

Presented by Cathy Ann Ball, VMD, MS

Scientific Symposium

Results of a New Flea/Tick Preventative Treatment, Vectra 3D™ in a National Clinical Trial


Summit VetPharm introduced the new flea/tick preventative Vectra 3D in September 2007 at the Central Veterinary Conference. The Vectra 3D formulation is built around the novel third-generation neonicotinoid molecule dinotefuran. Vectra 3D also contains the potent IGR, pyriproxyfen and the acaricide permethrin.

Summit VetPharm conducted a clinical trial with Vectra 3D during July/August, 2007 in 23 veterinary hospitals/clinics located in 11 states. There were 233 dogs enrolled; 197 were treated with Vectra 3D and 36 were treated with K9 Advantix® as a reference control.


Veterinarians randomly allocated dogs to treatment groups and administered each treatment. The veterinarians evaluated the applicator, instructions and formulation appearance on the dog. The owners did not know which treatment the pet dogs received. Owners evaluated the treatment site, appearance and animal acceptance of the treatment at 24 hours and 30 days post treatment during a telephone interview.

Results

Applicator Assessment - Very Easy




24 Hour Behavior/Well-Being/Habits




Vectra 3D™

24 Hour Appearance




Vectra 3D™


30 Day Behavior/Well-Being/Habits




Vectra 3D™



K9 Advantix®



K9 Advantix®



K9 Advantix®